Please login to the form below
droxidopa
This page shows the latest droxidopa news and features for those working in and with pharma, biotech and healthcare.
Lundbeck’s key products shine in Q2 but problems remain
Sales of Rexulti (brexpiprazole), Abilify Maintena (aripiprazole), Trintellix (vortioxetine) and Northera (droxidopa) increased by 20% to 44% in the quarter, resulting in overall sales of those key products coming in above
Latest news
-
Surging sales of Lundbeck's CNS drugs assist recovery
s disease - Northera (droxidopa) - romped away with a 136% rise to DKK 250m.
-
Lundbeck to cut 1,000 jobs in major restructure
Lundbeck's focus will now turn more to its newer drugs such as Brintellix (vortioxetine), Northera (droxidopa), Onfi (clobazam) and Abilify Maintena (aripriprazole) which saw a 190% growth in sales.
-
Lundbeck still feeling effects from Cipralex patent loss
and Northera (droxidopa) for a rare blood pressure disorder, which launched in the US last month.
-
Lundbeck agrees $658m deal to buy Chelsea Therapeutics
Chelsea's marketed product - Northera (droxidopa) - was given a green light by the US FDA in February as the first drug specifically approved to treat symptomatic neurogenic orthostatic hypotension (NOH), a
-
FDA approves Chelsea's rare blood pressure drug
The Food and Drug Administration (FDA) backed Northera capsules (droxidopa) to treat neurogenic orthostatic hypotension (NOH), a chronic drop in blood pressure that is found in patients with Parkinson's disease, ... Northera's active ingredient droxidopa
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Deal Watch table for June 2014
825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).
-
Pharma deals during May 2014
Chelsea has the recently FDA-approved droxidopa, the first and only symptomatic treatment for neurogenic orthostatic hypotension ready for launch later this year.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
